Dexcom Inc
Dexcom
DXCM · NASDAQ
Healthcare
Catalog as of September 15, 2026. Not a live market feed.
- Fiscal Year
- 2025
- Revenue
- $4.7B
- Assets
- $6.3B
- SEC filing
- DEF 14A
- Filed
- April 15, 2026
Executive Compensation
Compensation reported for Dexcom’s named executive officers, including salary, stock awards, incentive compensation, other compensation, and total compensation.
Kevin Sayer
Executive Chairman
$16.3M
Reported total
- Salary
- $1,213,515
- Stock awards
- $13,853,723
- Incentives
- $1,144,506
- Option awards
- $0
- Other
- $70,854
Jacob Leach
President & Chief Executive Officer
$8M
Reported total
- Salary
- $768,962
- Stock awards
- $5,936,062
- Incentives
- $1,164,780
- Option awards
- $0
- Other
- $116,156
Jereme Sylvain
EVP, Chief Financial Officer
$7.1M
Reported total
- Salary
- $646,623
- Stock awards
- $5,936,062
- Incentives
- $465,568
- Option awards
- $0
- Other
- $29,649
Jon Coleman
EVP, Chief Commercial Officer
$6.7M
Reported total
- Salary
- $491,507
- Stock awards
- $5,831,045
- Incentives
- $353,885
- Option awards
- $0
- Other
- $68,858
Michael Brown
EVP, Chief Legal Officer
$6.3M
Reported total
- Salary
- $631,627
- Stock awards
- $5,242,495
- Incentives
- $454,771
- Option awards
- $0
- Other
- $14,963
Sadie Stern
EVP, Chief Human Resources Officer
$6.3M
Reported total
- Salary
- $571,209
- Stock awards
- $5,242,495
- Incentives
- $411,270
- Option awards
- $0
- Other
- $28,157
Jacob Leach
President & Chief Executive Officer
$8M
Reported total · FY2025 · SCT Total as filed
Source: DEF 14A Summary Compensation Table, filed April 15, 2026.
- Salary
- $769K
- Stock Awards
- $5.9M
- Incentives
- $1.2M
- Other
- $116K
Historical Compensation
Jacob Leach total compensation, fiscal years 2023–2025.
| Fiscal Year | Salary | Stock Awards | Total Compensation |
|---|---|---|---|
| 2025 | $768,962 | $5,936,062 | $7,985,960 |
| 2024 | $682,498 | $5,229,163 | $5,922,271 |
| 2023 | $625,053 | $3,648,340 | $4,938,023 |
Named Executive Officers
Jacob Leach
President & Chief Executive Officer
Dexcom · DXCM
$8M
FY 2025 · DEF 14A
Kevin Sayer
Executive Chairman
Dexcom · DXCM
$16.3M
FY 2025 · DEF 14A
Jereme Sylvain
EVP, Chief Financial Officer
Dexcom · DXCM
$7.1M
FY 2025 · DEF 14A
Michael Brown
EVP, Chief Legal Officer
Dexcom · DXCM
$6.3M
FY 2025 · DEF 14A
Jon Coleman
EVP, Chief Commercial Officer
Dexcom · DXCM
$6.7M
FY 2025 · DEF 14A
Sadie Stern
EVP, Chief Human Resources Officer
Dexcom · DXCM
$6.3M
FY 2025 · DEF 14A
Source information
- Company
- Dexcom Inc
- Ticker
- DXCM · NASDAQ
- Filing type
- DEF 14A
- Fiscal year
- 2025
- Filing date
- April 15, 2026
- SEC accession number
- 0001093557-26-000061
Source: U.S. Securities and Exchange Commission, DEF 14A Summary Compensation Table. View SEC filing
Related Companies
Johnson & Johnson
JNJ · NYSE
Joaquin Duato
Chairman/CEO
$32.8M
FY 2025 reported total
View company →
UnitedHealth
UnitedHealth Group Incorporated
UNH · NYSE
Stephen Hemsley
Chief Executive Officer
$60.9M
FY 2025 reported total
View company →
AbbVie
AbbVie Inc.
ABBV · NYSE
Robert A. Michael
Chairman Of The Board And Chief Executive Officer
$32.5M
FY 2025 reported total
View company →
Abbott
Abbott Laboratories
ABT · NYSE
Robert B. Ford
Chairman Of The Board And Chief Executive Officer
$24.2M
FY 2025 reported total
View company →